Abstract
This study estimates the annual treatment cost of Jivi® compared to other EHL treatments in hemophilia A, Adynovate, Eloctate, and Esperoct, for patients aged 12 years and above, from a US payer perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
